Alterity Therapeutics Limited

Equities

ATH

AU0000043945

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:53 2024-05-31 EDT			5-day change	1st Jan Change
0.005 ^AUD	0.00%		0.00%	-28.57%

05-08	Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review	CI
05-08	Alterity Therapeutics on Track to Complete Phase Two Trial of Lead Drug Candidate in November	MT

David Stamler Joins Prana Biotechnology as Chief Medical Officer and Senior Vice President, Clinical Development

June 04, 2017 at 08:16 pm

David Stamler, M.D., has joined Prana Biotechnology Limited as Chief Medical Officer and Senior Vice President, Clinical Development, based in San Francisco. Prior to joining Prana, Dr. Stamler worked for Teva Pharmaceuticals as VP, Clinical Development and Therapeutic Head, Movement Disorders. Prior to Teva, Dr. Stamler was Chief Medical Officer at Auspex Pharmaceuticals Inc.

Latest news about Alterity Therapeutics Limited

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review	05-08	CI
Alterity Therapeutics on Track to Complete Phase Two Trial of Lead Drug Candidate in November	05-07	MT
Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases	04-29	CI
ADRs End Lower, Purple Biotech Ltd. Declines 29%	04-16	DJ
ADRs End Lower, Leju Holdings Ltd. Declines 72%	04-12	DJ
ADRs End Higher, Lixiang Education Holding Co. Ltd. Climbs 69%	04-11	DJ
ADRs Close Lower; VIA Optronics AG Declines 30%	04-10	DJ
Top Midday Gainers	04-10	MT
Alterity Therapeutics Receives AU$3.9 Million R&D Tax Refund	03-25	MT
Genetic Technologies Appoints CFO	03-25	MT
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-29	CI
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 30, 2023	02-28	CI
Alterity Therapeutics Raises AU$3.3 Million for Clinical Trials; Shares Fall 20%	02-22	MT
Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review	02-06	CI
Alterity Therapeutics Advances Phase Two Multiple System Atrophy Trial Following Committee Recommendation	02-06	MT
Alterity Therapeutics Completes Securities Purchase Plan	02-01	MT
Alterity Dispatches Documents Of Planned Share Sale	01-10	MT
Alterity Therapeutics Concludes Second Tranche of Placement of AU$3.5 Million; Shares Plunge 20%	01-07	MT
Alterity Therapeutics to Raise Up to AU$2 Million Via Share Purchase Plan	12-29	MT
Transcript : Alterity Therapeutics Limited - Shareholder/Analyst Call	12-28
Alterity Therapeutics Names Phillip Hains as Chief Financial Officer	12-21	MT
Alterity Therapeutics Limited Announces CFO Changes	12-21	CI
ADRs End Lower; Evaxion Biotech Declines 27%	12-05	DJ
Transcript : Alterity Therapeutics Limited - Special Call	12-05
Top Premarket Decliners	12-05	MT

Chart Alterity Therapeutics Limited

Duration

Period

More charts

Company Profile

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.

Sector

Biotechnology & Medical Research

Calendar

2025-02-26 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALTERITY THERAPEUTICS LIMITED	-28.57%	17.43M
MODERNA, INC.	+43.88%	58.06B
IQVIA HOLDINGS INC.	-6.08%	40.53B
LONZA GROUP AG	+37.52%	38.99B
ICON PUBLIC LIMITED COMPANY	+13.55%	26.7B
CELLTRION, INC.	-12.01%	26.56B
ALNYLAM PHARMACEUTICALS, INC.	-21.84%	18.98B
BIO-TECHNE CORPORATION	+0.10%	12.17B
UNITED THERAPEUTICS CORPORATION	+23.80%	12B
MEDPACE HOLDINGS, INC.	+24.65%	11.92B

Other Biotechnology & Medical Research